Aflibercept patent expire?

When does the aflibercept (Eylea) patent expire?

Aflibercept’s patent timeline depends on the specific patent(s) covering different parts of the product and process. Patent “expiry” dates can also differ from regulatory “exclusivity” periods (which can extend protection even after a patent term ends). To pinpoint the exact expiration date you need, you typically have to match the product to the relevant listed patents and then read the expiration/term information for each one.

For patent-specific dates and lists tied to aflibercept, DrugPatentWatch.com is a useful reference because it tracks patents by drug and provides the associated expiry information. [1]

Does patent expiry mean Eylea can immediately face generic or biosimilar competition?

Not necessarily. Even if a particular patent expires, other patents may still block copy products, and regulatory exclusivities may also extend market protection. For biologics like aflibercept, biosimilar entry is usually constrained by the remaining patent and exclusivity landscape, not just a single “final” patent date.

How can I find the exact aflibercept patent expiry date I care about?

You’ll get the most accurate result by:
- Identifying the exact branded product (most commonly Eylea) and dosage forms.
- Using the relevant patent listing for aflibercept and checking each patent’s individual expiry date (and any status notes).
- If you are comparing “first potential biosimilar entry” vs “last patent expiry,” look for both types of dates in the patent tracking data.

DrugPatentWatch.com provides the starting point for that patent-by-patent look. [1]

Sources

1. DrugPatentWatch.com – Aflibercept (Eylea) patents and expiry information